AU2016274633B2 - Methods for the production of TCR gamma delta+ T cells - Google Patents

Methods for the production of TCR gamma delta+ T cells Download PDF

Info

Publication number
AU2016274633B2
AU2016274633B2 AU2016274633A AU2016274633A AU2016274633B2 AU 2016274633 B2 AU2016274633 B2 AU 2016274633B2 AU 2016274633 A AU2016274633 A AU 2016274633A AU 2016274633 A AU2016274633 A AU 2016274633A AU 2016274633 B2 AU2016274633 B2 AU 2016274633B2
Authority
AU
Australia
Prior art keywords
cells
interleukin
cell
tcry6
culture medium
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2016274633A
Other languages
English (en)
Other versions
AU2016274633A1 (en
Inventor
Diogo Antonio Remechido ANJOS
Daniel Vargas Correia
Afonso Rocha MARTINS DE ALMEIDA
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GammaDelta Therapeutics Ltd
Original Assignee
GammaDelta Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GammaDelta Therapeutics Ltd filed Critical GammaDelta Therapeutics Ltd
Publication of AU2016274633A1 publication Critical patent/AU2016274633A1/en
Application granted granted Critical
Publication of AU2016274633B2 publication Critical patent/AU2016274633B2/en
Priority to AU2022205271A priority Critical patent/AU2022205271A1/en
Assigned to GAMMADELTA THERAPEUTICS LTD reassignment GAMMADELTA THERAPEUTICS LTD Request for Assignment Assignors: Lymphact - Lymphocyte Activation Technologies S. A.
Priority to AU2025202866A priority patent/AU2025202866A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2301—Interleukin-1 (IL-1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2302—Interleukin-2 (IL-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2304—Interleukin-4 (IL-4)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2307—Interleukin-7 (IL-7)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2315—Interleukin-15 (IL-15)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2321—Interleukin-21 (IL-21)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/24—Interferons [IFN]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/515—CD3, T-cell receptor complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/599—Cell markers; Cell surface determinants with CD designations not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/998—Proteins not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/11—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from blood or immune system cells
    • C12N2506/115—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from blood or immune system cells from monocytes, from macrophages

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AU2016274633A 2015-06-09 2016-06-08 Methods for the production of TCR gamma delta+ T cells Active AU2016274633B2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2022205271A AU2022205271A1 (en) 2015-06-09 2022-07-15 Methods for the production of TCR gamma delta+ T cells
AU2025202866A AU2025202866A1 (en) 2015-06-09 2025-04-23 Methods for the production of TCR gamma delta+ T cells

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
PT20151000047568 2015-06-09
PT2015047568 2015-06-09
PT20161000032002 2016-05-12
PT2016032002 2016-05-12
PCT/EP2016/063077 WO2016198480A1 (en) 2015-06-09 2016-06-08 Methods for the production of tcr gamma delta+ t cells

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2022205271A Division AU2022205271A1 (en) 2015-06-09 2022-07-15 Methods for the production of TCR gamma delta+ T cells

Publications (2)

Publication Number Publication Date
AU2016274633A1 AU2016274633A1 (en) 2018-02-01
AU2016274633B2 true AU2016274633B2 (en) 2022-04-21

Family

ID=56132913

Family Applications (3)

Application Number Title Priority Date Filing Date
AU2016274633A Active AU2016274633B2 (en) 2015-06-09 2016-06-08 Methods for the production of TCR gamma delta+ T cells
AU2022205271A Abandoned AU2022205271A1 (en) 2015-06-09 2022-07-15 Methods for the production of TCR gamma delta+ T cells
AU2025202866A Pending AU2025202866A1 (en) 2015-06-09 2025-04-23 Methods for the production of TCR gamma delta+ T cells

Family Applications After (2)

Application Number Title Priority Date Filing Date
AU2022205271A Abandoned AU2022205271A1 (en) 2015-06-09 2022-07-15 Methods for the production of TCR gamma delta+ T cells
AU2025202866A Pending AU2025202866A1 (en) 2015-06-09 2025-04-23 Methods for the production of TCR gamma delta+ T cells

Country Status (9)

Country Link
US (2) US11166983B2 (https=)
EP (2) EP3307875B1 (https=)
JP (1) JP6799895B2 (https=)
CN (2) CN108350428B (https=)
AU (3) AU2016274633B2 (https=)
CA (1) CA2988050A1 (https=)
EA (1) EA201890013A1 (https=)
WO (1) WO2016198480A1 (https=)
ZA (1) ZA201800121B (https=)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016081518A2 (en) * 2014-11-17 2016-05-26 Adicet Bio, Inc. Engineered gamma delta t-cells
KR102663157B1 (ko) 2015-06-09 2024-05-13 감마델타 테라퓨틱스 엘티디 Ｔｃｒ감마 델타 양성 ｔ 세포의 생산 방법
EP4148124A1 (en) * 2015-10-30 2023-03-15 Cancer Research Technology Limited Expansion of non-haematopoietic tissue-resident gamma delta t cells and uses of these cells
EP3454870A4 (en) * 2016-05-12 2020-03-04 Adicet Bio Inc. METHOD FOR SELECTIVE EXPANSION OF GAMMA DELTA T CELL POPULATIONS AND COMPOSITIONS THEREOF
AU2017326173B2 (en) * 2016-09-16 2022-08-18 Baylor College Of Medicine Platform for activation and expansion of virus-specific T-cells
GB201707048D0 (en) * 2017-05-03 2017-06-14 King S College London Expansion of gamma delta cells, compositions, and methods of use thereof
WO2018229163A1 (en) * 2017-06-14 2018-12-20 King's College London Methods of activating v delta 2 negative gamma delta t cells
WO2019099744A1 (en) 2017-11-15 2019-05-23 Adicet Bio, Inc. METHODS FOR SELECTIVE EXPANSION OF δ3 γδ T-CELL POPULATIONS AND COMPOSITIONS THEREOF
US10519236B2 (en) * 2018-01-23 2019-12-31 New York University Antibodies specific to delta 1 chain of T cell receptor
GB201804701D0 (en) 2018-03-23 2018-05-09 Gammadelta Therapeutics Ltd Lymphocytes expressing heterologous targeting constructs
AU2019354391A1 (en) 2018-10-01 2021-05-06 Adicet Therapeutics, Inc. Compositions and methods regarding engineered and non- engineered γδ-Τ cells for treatment of hematological tumors
CN113272016A (zh) 2018-10-01 2021-08-17 阿迪塞特生物股份有限公司 关于治疗实体肿瘤的工程化和非工程化γδ-T细胞的组合物和方法
GB201818243D0 (en) 2018-11-08 2018-12-26 Gammadelta Therapeutics Ltd Methods for isolating and expanding cells
US12084500B2 (en) 2019-01-23 2024-09-10 New York University Antibodies specific to delta 1 chain of T cell receptor
US20220088074A1 (en) * 2019-02-21 2022-03-24 Regents Of The University Of Minnesota Genetically modified gamma delta t cells and methods of making and using
MX2021015448A (es) * 2019-06-14 2022-06-08 G Tech Bio Llc Células linfocíticas activadas y métodos para usarlas para tratar cáncer y afecciones infecciosas.
US20220290101A1 (en) 2019-08-16 2022-09-15 GammaDelta Therapeutics Limited Ex vivo gamma delta t cell populations
CA3145523A1 (en) 2019-08-16 2021-02-25 GammaDelta Therapeutics Limited Therapeutic uses of anti-tcr delta variable 1 antibodies
EP4045635A4 (en) * 2019-10-17 2023-10-25 The University of Hong Kong METHODS FOR PREPARING EXOSOMES DERIVED FROM T-V LYMPHOCYTES FOR THE TREATMENT OF CANCERS ASSOCIATED WITH EPSTEIN-BARR VIRUS
US20210130461A1 (en) 2019-10-31 2021-05-06 Morphosys Ag Anti-tumor combination therapy comprising anti-cd19 antibody and gamma delta t-cells
GB202002581D0 (en) * 2020-02-24 2020-04-08 Gammadelta Therapeutics Ltd Novel antibodies
KR20230013022A (ko) 2020-03-20 2023-01-26 감마델타 테라퓨틱스 엘티디 골수성 악성종양의 치료를 위한 v 델타1+ t 세포
US20210290674A1 (en) * 2020-03-20 2021-09-23 GammaDelta Therapeutics Ltd. Methods for treating myeloid malignancies
CN113913384A (zh) * 2020-07-09 2022-01-11 杭州优凯瑞医药科技有限公司 一种制备靶点特异性nk细胞的方法及其应用
EP4198120A4 (en) * 2020-08-14 2024-05-08 Shanghai Xinghua Bio Pharmaceutical Science & Technology Co., Ltd METHOD FOR PREPARING UNIVERSAL IMMUNE CELLS AND THEIR USE
LT4269444T (lt) 2020-08-14 2024-09-25 GammaDelta Therapeutics Limited Daugiaspecifiniai anti-tcr kintamos delta 1 antikūnai
CA3202233A1 (en) * 2020-11-18 2022-05-27 Kiromic BioPharma, Inc. Gamma-delta t cell manufacturing processes and chimeric pd1 receptor molecules
TW202246338A (zh) * 2021-02-17 2022-12-01 英商適應生物治療有限公司 抗ＴＣＲδ可變1抗體
AU2022222299A1 (en) 2021-02-17 2023-09-07 F-Star Therapeutics Limited Multispecific anti-tcr delta variable 1 antibodies
KR20240040799A (ko) 2021-08-03 2024-03-28 감마델타 테라퓨틱스 엘티디 감마 델타 t 세포 및 이의 조성물의 조작
MX2024010047A (es) 2022-02-16 2024-08-26 Priothera Sas Metodos de tratamiento con celulas car en combinacion con moduladores del receptor s1p.
WO2023194915A1 (en) 2022-04-04 2023-10-12 Gammadelta Therapeutics Ltd Novel gene armoring
GB202204926D0 (en) 2022-04-04 2022-05-18 Gammadelta Therapeutics Ltd Method for expanding gammadelta T cells
US11750950B1 (en) * 2022-05-26 2023-09-05 Omnivision Technologies, Inc. Voltage domain global shutter readout circuit timing
CN115678846B (zh) * 2022-09-01 2023-06-16 广东龄值生物科技有限公司 一种肿瘤特异性γδT细胞及其制备方法
EP4680729A1 (en) * 2023-03-17 2026-01-21 Legend Biotech Ireland Limited Methods of culturing v delta 1 t cells
EP4687923A1 (en) 2023-04-07 2026-02-11 Takeda Pharmaceutical Company Limited T cells for use in treating relapsed or refractory acute myeloid leukemia
WO2026013616A1 (en) 2024-07-10 2026-01-15 Takeda Pharmaceutical Company Limited Compositions and methods for treating cancer
WO2026033421A1 (en) 2024-08-05 2026-02-12 Takeda Pharmaceutical Company Limited IDENTIFICATION OF SUITABLE DONORS OF γδ T CELLS

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000026347A1 (en) * 1998-11-04 2000-05-11 Hemosol Inc. Methods for the production of tcr gamma delta t cells
US20140141513A1 (en) * 2011-05-19 2014-05-22 Instituto De Medicina Molecular Cell line of lymphocytes comprising gamma-delta t cells, composition and production method thereof
WO2015061694A2 (en) * 2013-10-25 2015-04-30 Board Of Regents, The University Of Texas System Polyclonal gamma delta t cells for immunotherapy

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE449162T1 (de) 2000-04-03 2009-12-15 Therapure Biopharma Inc Herstellung von tcr gamma delta t-zellen
US20030157060A1 (en) 2000-04-03 2003-08-21 Bell David N Production of tcr gamma delta t cells
EP1778836B1 (en) * 2004-08-19 2010-08-04 University College Cardiff Consultants Limited Preparation of antigen-presenting human gamma delta t cells and use in immunotherapy
CN101313061B (zh) * 2005-11-18 2013-05-15 大学健康网络 扩增双阴性t细胞的方法
WO2008111430A1 (ja) * 2007-03-09 2008-09-18 Takara Bio Inc. γδＴ細胞集団の製造方法
BR112013009454B1 (pt) 2010-10-21 2018-10-23 Syngenta Limited método para redução da viscosidade de um concentrado agroquímico aquoso, concentrado agroquímico aquoso, utilização de um sulfonato de arila e isopirazam para redução da viscosidade de um concentrado agroquímico aquoso e método para controlar ou prevenir a infestação de plantas por micro-organismos fitopatógenos
EP3484862B1 (en) 2016-07-18 2021-09-01 Arthrosi Therapeutics, Inc. Compounds, compositions and methods for treating or preventing a symptom associated with gout or hyperuricemia
CN106399245A (zh) * 2016-11-30 2017-02-15 广州赛莱拉干细胞科技股份有限公司 一种γδT细胞的培养方法

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000026347A1 (en) * 1998-11-04 2000-05-11 Hemosol Inc. Methods for the production of tcr gamma delta t cells
US20140141513A1 (en) * 2011-05-19 2014-05-22 Instituto De Medicina Molecular Cell line of lymphocytes comprising gamma-delta t cells, composition and production method thereof
WO2015061694A2 (en) * 2013-10-25 2015-04-30 Board Of Regents, The University Of Texas System Polyclonal gamma delta t cells for immunotherapy

Also Published As

Publication number Publication date
CN114958738A (zh) 2022-08-30
EP3307875A1 (en) 2018-04-18
EP3623468A1 (en) 2020-03-18
EA201890013A1 (ru) 2018-07-31
US11166983B2 (en) 2021-11-09
AU2025202866A1 (en) 2025-05-15
AU2022205271A1 (en) 2022-08-11
CN108350428A (zh) 2018-07-31
US20250152630A1 (en) 2025-05-15
EP3307875B1 (en) 2021-12-15
JP6799895B2 (ja) 2020-12-16
US20180169147A1 (en) 2018-06-21
NZ738912A (en) 2025-05-02
JP2018516586A (ja) 2018-06-28
ZA201800121B (en) 2019-08-28
CA2988050A1 (en) 2016-12-15
WO2016198480A1 (en) 2016-12-15
CN108350428B (zh) 2022-04-22
HK1245831A1 (zh) 2018-08-31
AU2016274633A1 (en) 2018-02-01

Similar Documents

Publication Publication Date Title
US20250152630A1 (en) Methods for the production of tcr gamma delta + t cells
US12178832B2 (en) Methods for the production of TCR gamma delta + t cells
CN104321425B (zh) 用于诱导和扩增源自外周血单个核细胞的自然杀伤细胞的方法
US20140120072A1 (en) Method for amplifying nk cells
JP6073417B2 (ja) 自然殺害細胞増殖方法、及び自然殺害細胞増殖用の組成物
JP5840876B2 (ja) Ｎｋ細胞を増幅するための組成物及び方法
US6537812B1 (en) Methods for the production of TcRγδ+ T cells
Mou et al. 2B4 inhibits the apoptosis of natural killer cells through phosphorylated extracellular signal-related kinase/B-cell lymphoma 2 signal pathway
CA2405050C (en) Production of tcr gamma delta t cells
Schilling et al. IRX-2, a novel biologic, favors the expansion of T effector over T regulatory cells in a human tumor microenvironment model
HK40024937A (en) Methods for the production of tcr gamma delta+ t cells
US20030157060A1 (en) Production of tcr gamma delta t cells
HK1245831B (en) Methods for the production of tcr gamma delta+ t cells
CN113939302A (zh) 医药组合物
EA043082B1 (ru) Способы получения tcr гамма дельта+ т-клеток
TWI778302B (zh) 用於體外擴增暨活化自然殺手細胞之細胞培養基
TW202118868A (zh) 體外擴增暨活化自然殺手細胞之方法及其醫藥組合物
CN112779216A (zh) 体外扩增和活化自然杀伤细胞的方法及其药物组合物

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
PC Assignment registered

Owner name: GAMMADELTA THERAPEUTICS LTD

Free format text: FORMER OWNER(S): LYMPHACT - LYMPHOCYTE ACTIVATION TECHNOLOGIES S. A.